Fibrocell Science, Inc.
已退市CIK 357097fmd_1CWEZE79JFV9Z594NMPFTNGM6R制造业 · 医药制剂模板: 标准
覆盖范围: 2004年1月01日 至 2019年9月30日，共 40 个期间
| 项目 | FY2007 | FY2008 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| 营业总收入 | – | – | – | – | 0 | 0 | 0 | 0 | 0 | 0 |
| 营业成本 | – | – | 0 | 8 | 8 | 2 | 1 | 1 | 0 | – |
| 净利息收入 | – | – | – | (1) | 0 | 0 | 0 | (0) | 0 | 0 |
| 毛利润 | – | – | (0) | (8) | (7) | (2) | (0) | (0) | 0 | – |
| 研发费用 | – | – | 7 | 10 | 4 | 8 | 10 | 8 | 7 | 6 |
| 销售、一般及管理费用 | – | – | 13 | 12 | 9 | 10 | 11 | 10 | 7 | 6 |
| 营业费用合计 | – | – | – | – | – | – | – | – | 19 | 12 |
| 营业利润 | – | – | (20) | (29) | (31) | (30) | (37) | (26) | (19) | (12) |
| 利息费用 | – | – | 1 | 1 | (0) | – | 0 | 0 | 1 | 1 |
| 其他营业外收入（支出） | – | – | – | – | – | – | 0 | (0) | – | – |
| 税前利润 | – | – | (24) | (13) | (32) | (26) | (34) | (15) | (16) | (10) |
| 所得税费用 | – | – | – | – | 0 | 0 | 0 | 0 | 0 | 0 |
| 持续经营净利润 | – | – | (24) | (13) | (32) | (26) | (34) | (15) | (16) | (10) |
| 净利润 | (36) | (33) | (24) | (13) | (32) | (26) | (34) | (15) | (16) | (10) |
| 归属于普通股股东的净利润 | – | – | (24) | (13) | (32) | (26) | (34) | (15) | (21) | (11) |